183 related articles for article (PubMed ID: 35762079)
1. Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial.
Iglesias JF; Valgimigli M; Carbone F; Lauriers N; Masci PG; Degrauwe S
Cardiol J; 2022; 29(4):591-600. PubMed ID: 35762079
[TBL] [Abstract][Full Text] [Related]
2. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
[TBL] [Abstract][Full Text] [Related]
3. Differential impact of fentanyl and morphine doses on ticagrelor-induced platelet inhibition in ST-segment elevation myocardial infarction: a subgroup analysis from the PERSEUS randomized trial.
Garin D; Degrauwe S; Carbone F; Musayeb Y; Lauriers N; Valgimigli M; Iglesias JF
Front Cardiovasc Med; 2024; 11():1324641. PubMed ID: 38628315
[TBL] [Abstract][Full Text] [Related]
4. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
Franchi F; Rollini F; Cho JR; Bhatti M; DeGroat C; Ferrante E; Dunn EC; Nanavati A; Carraway E; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2015 Sep; 8(11):1457-1467. PubMed ID: 26404199
[TBL] [Abstract][Full Text] [Related]
5. The MOVEMENT Trial.
Holm M; Tornvall P; Henareh L; Jensen U; Golster N; Alström P; Santos-Pardo I; Witt N; Fedchenko N; Venetsanos D; Beck O; van der Linden J
J Am Heart Assoc; 2019 Jan; 8(2):e010152. PubMed ID: 30636504
[TBL] [Abstract][Full Text] [Related]
6. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study.
Silvain J; Storey RF; Cayla G; Esteve JB; Dillinger JG; Rousseau H; Tsatsaris A; Baradat C; Salhi N; Hamm CW; Lapostolle F; Lassen JF; Collet JP; Ten Berg JM; Van't Hof AW; Montalescot G
Thromb Haemost; 2016 Aug; 116(2):369-78. PubMed ID: 27196998
[TBL] [Abstract][Full Text] [Related]
7. Effects of Fentanyl Versus Morphine on Ticagrelor-Induced Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: The PERSEUS Randomized Trial.
Iglesias JF; Valgimigli M; Carbone F; Lauriers N; Giorgio Masci P; Degrauwe S
Circulation; 2020 Dec; 142(25):2479-2481. PubMed ID: 33347326
[No Abstract] [Full Text] [Related]
8. Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial.
Ibrahim K; Shah R; Goli RR; Kickler TS; Clarke WA; Hasan RK; Blumenthal RS; Thiemann DR; Resar JR; Schulman SP; McEvoy JW
Thromb Haemost; 2018 Aug; 118(8):1409-1418. PubMed ID: 29972861
[TBL] [Abstract][Full Text] [Related]
9. Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.
Tavenier AH; Hermanides RS; Ottervanger JP; Tolsma R; van Beurden A; Slingerland RJ; Ter Horst PGJ; Gosselink ATM; Dambrink JE; van Leeuwen MAH; Roolvink V; Kedhi E; Klungel OH; Belitser SV; Angiolillo DJ; Pustjens T; Rasoul S; Gho B; Stein M; Ruiters L; van 't Hof AWJ
Eur Heart J Cardiovasc Pharmacother; 2022 Jan; 8(1):4-12. PubMed ID: 32730628
[TBL] [Abstract][Full Text] [Related]
10. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study.
Adamski P; Sikora J; Laskowska E; Buszko K; Ostrowska M; Umińska JM; Sikora A; Skibińska N; Sobczak P; Adamska U; Rość D; Kubica A; Paciorek P; Marszałł MP; Navarese EP; Gorog DA; Kubica J
PLoS One; 2017; 12(10):e0186013. PubMed ID: 29023473
[TBL] [Abstract][Full Text] [Related]
11. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.
Parodi G; Valenti R; Bellandi B; Migliorini A; Marcucci R; Comito V; Carrabba N; Santini A; Gensini GF; Abbate R; Antoniucci D
J Am Coll Cardiol; 2013 Apr; 61(15):1601-6. PubMed ID: 23500251
[TBL] [Abstract][Full Text] [Related]
12. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
[TBL] [Abstract][Full Text] [Related]
13. Ticagrelor Pharmacokinetics and Pharmacodynamics in Chinese Patients with STEMI and NSTEMI Without Opioid Administration.
Wang Y; Wu H; Chen Y; Wang Q; Qian J; Ge J
Adv Ther; 2020 Oct; 37(10):4220-4232. PubMed ID: 32770531
[TBL] [Abstract][Full Text] [Related]
14. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
15. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.
Kubica J; Adamski P; Ostrowska M; Sikora J; Kubica JM; Sroka WD; Stankowska K; Buszko K; Navarese EP; Jilma B; Siller-Matula JM; Marszałł MP; Rość D; Koziński M
Eur Heart J; 2016 Jan; 37(3):245-52. PubMed ID: 26491112
[TBL] [Abstract][Full Text] [Related]
16. Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial.
Vivas D; Jiménez JJ; Martín-Asenjo R; Bernardo E; Ortega-Pozzi MA; Gómez-Polo JC; Moreno G; Vilacosta I; Pérez-Villacastín J; Fernández-Ortiz A
J Thromb Thrombolysis; 2023 Feb; 55(2):203-210. PubMed ID: 36480147
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose.
Holm M; Tornvall P; Westerberg J; Rihan Hye S; van der Linden J
Platelets; 2017 Nov; 28(7):706-711. PubMed ID: 28150519
[TBL] [Abstract][Full Text] [Related]
18. Negative Impact of ST-Segment Elevation Myocardial Infarction and Morphine Dose on Ticagrelor Uptake and Pharmacodynamics: A Population PK/PD Analysis of Pooled Individual Participant Data.
Konecki C; Holm M; Djerada Z
Clin Pharmacokinet; 2023 Jun; 62(6):905-920. PubMed ID: 37097605
[TBL] [Abstract][Full Text] [Related]
19. Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Liu HL; Wei YJ; Jin ZG; Zhang J; Ding P; Yang SL; Luo JP; Ma DX; Liu Y; Han W
Medicine (Baltimore); 2016 May; 95(22):e3756. PubMed ID: 27258504
[TBL] [Abstract][Full Text] [Related]
20. Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine.
Lapostolle F; Van't Hof AW; Hamm CW; Stibbe O; Ecollan P; Collet JP; Silvain J; Lassen JF; Heutz WMJM; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Goodman SG; Hammett CJ; Huber K; Janzon M; Merkely B; Storey RF; Ten Berg J; Zeymer U; Licour M; Tsatsaris A; Montalescot G;
Am J Cardiovasc Drugs; 2019 Apr; 19(2):173-183. PubMed ID: 30353444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
